Sharleen O'Reilly

Prof. Sharleen O'Reilly

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2010 in American Journal of Psychiatry
Verified
Journal Article
Closed access
PDF file
FJFelice N. Jacka
Felice N. Jacka
JPJulie A. Pasco
Julie A. Pasco
AMArnstein Mykletun
Arnstein Mykletun
LWLana J. Williams
Lana J. Williams
AHAllison Hodge
Allison Hodge
MBMichael Berk
Michael Berk

26 July 2016 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
SOSharleen O'reilly
Sharleen O'reilly
JDJames A. Dunbar
James A. Dunbar
VVVincent Versace
Vincent Versace
EJEdward Janus
Edward Janus
JBJames D. Best
James D. Best
MGMAGDA Study Group
MAGDA Study Group
Gestational diabetes mellitus (GDM) is an increasingly prevalent risk factor for type 2 diabetes. We evaluated the effectiveness of a group-based lifestyle modification program in mothers with prior GDM within their first postnatal year. In this study, 573 women were randomised to either the intervention (n = 284) or usual care (n = 289). At baseline, 10% had impaired glucose tolerance and 2% impaired fasting glucose. The diabetes prevention intervention comprised one individual session, five group sessions, and two telephone sessions. Primary outcomes were changes in diabetes risk factors (weight, waist circumference, and fasting blood glucose), and secondary outcomes included achievement of lifestyle modification goals and changes in depression score and cardiovascular disease risk factors. The mean changes (intention-to-treat [ITT] analysis) over 12 mo were as follows: −0.23 kg body weight in intervention group (95% CI −0.89, 0.43) compared with +0.72 kg in usual care group (95% CI 0.09, 1.35) (change difference −0.95 kg, 95% CI −1.87, −0.04; group by treatment interaction p = 0.04); −2.24 cm waist measurement in intervention group (95% CI −3.01, −1.42) compared with −1.74 cm in usual care group (95% CI −2.52, −0.96) (change difference −0.50 cm, 95% CI −1.63, 0.63; group by treatment interaction p = 0.389); and +0.18 mmol/l fasting blood glucose in intervention group (95% CI 0.11, 0.24) compared with +0.22 mmol/l in usual care group (95% CI 0.16, 0.29) (change difference −0.05 mmol/l, 95% CI −0.14, 0.05; group by treatment interaction p = 0.331). Only 10% of women attended all sessions, 53% attended one individual and at least one group session, and 34% attended no sessions. Loss to follow-up was 27% and 21% for the intervention and control groups, respectively, primarily due to subsequent pregnancies. Study limitations include low exposure to the full intervention and glucose metabolism profiles being near normal at baseline. Although a 1-kg weight difference has the potential to be significant for reducing diabetes risk, the level of engagement during the first postnatal year was low. Further research is needed to improve engagement, including participant involvement in study design; it is potentially more effective to implement annual diabetes screening until women develop prediabetes before offering an intervention. Australian New Zealand Clinical Trials Registry ACTRN12610000338066

1 November 2006 in The Journal of Nutrition
Verified
Journal Article
Open access
PDF file
GWGillian R. Wasson
Gillian R. Wasson
AMAngela P. McGlynn
Angela P. McGlynn
HMHelene Mcnulty
Helene Mcnulty
SOSharleen O'reilly
Sharleen O'reilly
VMValerie J. McKelvey-Martin
Valerie J. McKelvey-Martin
CDC. Stephen Downes
C. Stephen Downes
There is increasing evidence to suggest that reduced folate status may be a causative factor in carcinogenesis, particularly colorectal carcinogenesis. Folate is essential for the synthesis of S-adenosylmethionine, the methyl donor required for all methylation reactions in the cell, including the methylation of DNA. Global DNA hypomethylation appears to be an early, and consistent, molecular event in carcinogenesis. We have examined the effects of folate depletion on human-derived cultured colon carcinoma cells using 2 novel modifications to the Comet (single cell gel electrophoresis) assay to detect global DNA hypomethylation and gene region–specific DNA hypomethylation. Colon cells cultured in folate-free medium for 14 d showed a significant increase in global DNA hypomethylation compared with cells grown in medium containing 3μmol/L folic acid. This was also true at a gene level, with folate-deprived cells showing significantly more DNA hypomethylation in the region of the p53 gene. In both cases, the effects of folate depletion were completely reversed by the reintroduction of folic acid to the cells. These results confirm that decreased folate levels are capable of inducing DNA hypomethylation in colon cells and particularly in the region of the p53 gene, suggesting that a more optimal folate status in vivo may normalize any DNA hypomethylation, offering potential protective effects against carcinogenesis. This study also introduces 2 novel functional biomarkers of DNA hypomethylation and demonstrates their suitability to detect folate depletion–induced molecular changes.

27 August 2015 in Obesity Reviews
Verified
Journal Article
Closed access
PDF file
SLS. Lim
S. Lim
SOSharleen O'reilly
Sharleen O'reilly
HBH. Behrens
H. Behrens
TSTimothy Skinner
Timothy Skinner
IEI. Ellis
I. Ellis
JDJ. A Dunbar
J. A Dunbar

3 April 2019 in Obesity Reviews
Verified
Journal Article
Closed access
PDF file
SLSiew Lim
Siew Lim
XLXinyu Liang
Xinyu Liang
Briony HillBriony Hill
Briony Hill
HTHelena Teede
Helena Teede
LMLisa J. Moran
Lisa J. Moran
SOSharleen O'reilly
Sharleen O'reilly

24 October 2022 in Obesity Facts
Verified
Journal Article
Open access
PDF file
CBCathy Breen
Cathy Breen
JOJean O’cOnnell
Jean O’cOnnell
JGJustin Geoghegan
Justin Geoghegan
DODonal O’sHea
Donal O’sHea
SBSusie Birney
Susie Birney
RYRuth Yoder
Ruth Yoder
Background: This Clinical Practice Guideline (CPG) for the management of obesity in adults in Ireland, adapted from the Canadian CPG, defines obesity as a complex chronic disease characterised by excess or dysfunctional adiposity that impairs health. The guideline reflects substantial advances in the understanding of the determinants, pathophysiology, assessment, and treatment of obesity. Summary: It shifts the focus of obesity management toward improving patient-centred health outcomes, functional outcomes, and social and economic participation, rather than weight loss alone. It gives recommendations for care that are underpinned by evidence-based principles of chronic disease management; validate patients’ lived experiences; move beyond simplistic approaches of “eat less, move more” and address the root drivers of obesity. Key Messages: People living with obesity face substantial bias and stigma, which contribute to increased morbidity and mortality independent of body weight. Education is needed for all healthcare professionals in Ireland to address the gap in skills, increase knowledge of evidence-based practice, and eliminate bias and stigma in healthcare settings. We call for people living with obesity in Ireland to have access to evidence-informed care, including medical, medical nutrition therapy, physical activity and physical rehabilitation interventions, psychological interventions, pharmacotherapy, and bariatric surgery. This can be best achieved by resourcing and fully implementing the Model of Care for the Management of Adult Overweight and Obesity. To address health inequalities, we also call for the inclusion of obesity in the Structured Chronic Disease Management Programme and for pharmacotherapy reimbursement, to ensure equal access to treatment based on health-need rather than ability to pay.